Douglas Tsao

Catherine Novack

Brian Kemp Dolliver

Will Hidell

- **Daré Bioscience** received a **$4.0 million** non-dilutive funding installment, bringing the total grant funding received to approximately **$41.8 million** out of an up to **$49 million** committed grant.  **[1401914_b650e4ff6b504ea79e89ceb56dfe7285_0]** 
- This funding supports the development of **DARE-LARC1**, a preclinical-stage long-acting reversible contraceptive (LARC) that utilizes the company's intelligent drug delivery system (DARE-IDDS) platform.  **[1401914_b650e4ff6b504ea79e89ceb56dfe7285_0]** 
- The **DARE-IDDS platform** has broader market potential beyond reproductive health, including applications in **obesity, diabetes, and other chronic conditions**.  **[1401914_b650e4ff6b504ea79e89ceb56dfe7285_0]** **[1401914_b650e4ff6b504ea79e89ceb56dfe7285_2]** 
- The company is eligible for up to an additional **$7.1 million** in non-dilutive funding for the DARE-LARC1 program, contingent on achieving specified milestones.  **[1401914_b650e4ff6b504ea79e89ceb56dfe7285_2]**

Dare Bioscience (DARE)